Dolastatin-10 in Metastatic Melanoma: a Phase II and Pharmokinetic Trial of the California Cancer Consortium

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2001 Sep 20

PMID 11561695

Citations 13

Authors

K Margolin

J Longmate

T W Synold

D R Gandara

J Weber

R Gonzalez

M J Johansen

R Newman

T Baratta

J H Doroshow

Affiliations

Soon will be listed here.

Abstract

Dolastatin-10 is a novel pentapeptide agent originally isolated from the marine mollusk Dolabella auricularia with a mechanism of antitumor activity that involves the inhibition of microtubule assembly. We performed a Phase II trial of Dolastatin-10, 400 microg/m2 in patients with advanced melanoma who had received no prior chemotherapy. Dolastatin-10 pharmokinetics were evaluated in a subset of patients following courses 1 and 2. Twelve patients were treated with a median of 2 cycles of Dolastatin-10, and no patient experienced an objective response. The only grade >2 toxicities were grade 3 neutropenia uncomplicated by infection, occurring in 4 patients following the first treatment cycle. The total systemic clearance and volume of distribution at steady-state were 2.61 +/- 1.9 L/h/m2 and 28.4 +/- 13 L/m2, respectively. Due to prolonged terminal elimination. Dolastatin-10 plasma concentrations of greater than 1 nM were sustained for 24 h in all patients studied. Dolastatin-10 is unlikely to have substantial activity in the treatment of melanoma.

Citing Articles

The intriguing chemistry and biology of sulfur-containing natural products from marine microorganisms (1987-2020).

Hai Y, Wei M, Wang C, Gu Y, Shao C Mar Life Sci Technol. 2023; 3(4):488-518.

PMID: 37073258 PMC: 10077240. DOI: 10.1007/s42995-021-00101-2.

Physiological and Clinical Aspects of Bioactive Peptides from Marine Animals.

Chakniramol S, Wierschem A, Cho M, Bashir K Antioxidants (Basel). 2022; 11(5).

PMID: 35624884 PMC: 9137753. DOI: 10.3390/antiox11051021.

Preparation of Nereid oligopeptide and investigation of the mechanism underlying the induction of apoptosis in human lung cancer H1299 cells.

Zhang G, Li H, Liu S, Lu M, Tang L, Sun L Mol Med Rep. 2022; 25(6).

PMID: 35425994 PMC: 9052003. DOI: 10.3892/mmr.2022.12710.

Mitotic Poisons in Research and Medicine.

Skubnik J, Jurasek M, Ruml T, Rimpelova S Molecules. 2020; 25(20).

PMID: 33053667 PMC: 7587177. DOI: 10.3390/molecules25204632.

Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications.

Akaiwa M, Martin T, Mendelsohn B ACS Omega. 2018; 3(5):5212-5221.

PMID: 30023909 PMC: 6045487. DOI: 10.1021/acsomega.8b00093.

References

Miyashita T, Harigai M, Hanada M, Reed J . Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994; 54(12):3131-5. View

Kalemkerian G, Ou X, Adil M, Rosati R, Khoulani M, Madan S . Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol. 1999; 43(6):507-15. DOI: 10.1007/s002800050931. View

Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S . Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999; 17(3):968-75. DOI: 10.1200/JCO.1999.17.3.968. View

Yamaoka K, Nakagawa T, Uno T . Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978; 6(2):165-75. DOI: 10.1007/BF01117450. View

Hu Z, Gignac S, Quentmeier H, Pettit G, Drexler H . Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leuk Res. 1993; 17(4):333-9. DOI: 10.1016/0145-2126(93)90020-l. View

Sparrow L, Soong R, Dawkins H, Iacopetta B, Heenan P . p53 gene mutation and expression in naevi and melanomas. Melanoma Res. 1995; 5(2):93-100. DOI: 10.1097/00008390-199504000-00004. View

Khayat D, Borel C, Tourani J, Benhammouda A, Antoine E, Rixe O . Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993; 11(11):2173-80. DOI: 10.1200/JCO.1993.11.11.2173. View

Poremba C, Yandell D, Metze D, Kamanabrou D, Bocker W, Dockhorn-Dworniczak B . Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res. 1995; 7(7-8):331-9. View

Chapman P, Einhorn L, Meyers M, Saxman S, Destro A, Panageas K . Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17(9):2745-51. DOI: 10.1200/JCO.1999.17.9.2745. View

10.

Pulaski L, Jedlitschky G, Leier I, Buchholz U, Keppler D . Identification of the multidrug-resistance protein (MRP) as the glutathione-S-conjugate export pump of erythrocytes. Eur J Biochem. 1996; 241(2):644-8. DOI: 10.1111/j.1432-1033.1996.00644.x. View

11.

El-Deiry W, Tokino T, Velculescu V, Levy D, Parsons R, Trent J . WAF1, a potential mediator of p53 tumor suppression. Cell. 1993; 75(4):817-25. DOI: 10.1016/0092-8674(93)90500-p. View

12.

Toppmeyer D, Slapak C, Croop J, Kufe D . Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol. 1994; 48(3):609-12. DOI: 10.1016/0006-2952(94)90292-5. View

13.

Hartmann A, Blaszyk H, Cunningham J, McGovern R, Schroeder J, Helander S . Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer. 1996; 67(3):313-7. DOI: 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U. View

14.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

15.

Saenz-Santamaria M, McNutt N, Bogdany J, Shea C . p53 expression is rare in cutaneous melanomas. Am J Dermatopathol. 1995; 17(4):344-9. DOI: 10.1097/00000372-199508000-00007. View

16.

Bai R, Pettit G, Hamel E . Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990; 39(12):1941-9. DOI: 10.1016/0006-2952(90)90613-p. View

17.

Pitot H, McElroy Jr E, Reid J, Windebank A, Sloan J, Erlichman C . Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999; 5(3):525-31. View

18.

Garteiz D, Madden T, Beck D, Huie W, McManus K, Abbruzzese J . Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial. Cancer Chemother Pharmacol. 1998; 41(4):299-306. DOI: 10.1007/s002800050743. View

19.

Madden T, Tran H, Beck D, Huie R, Newman R, Pusztai L . Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 2000; 6(4):1293-301. View

20.

Keilholz U, Goey S, Punt C, Proebstle T, SALZMANN R, Scheibenbogen C . Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997; 15(7):2579-88. DOI: 10.1200/JCO.1997.15.7.2579. View